Libera Bio is a biopharmaceutical company focused on developing innovative therapeutics to tackle unmet medical needs in oncology, particularly by targeting "undruggable" intracellular targets. The company utilizes its proprietary Multifunctional Polymeric Nanoparticles (MPN Technology®) to facilitate the delivery of large biological molecules, such as monoclonal antibodies, directly into tumor and metastatic cells. This technology is designed to protect these biologics in the bloodstream after intravenous administration, enhancing their ability to engage with intracellular targets that have historically been difficult to reach. By collaborating with oncology biopharma partners, Libera Bio aims to create breakthrough treatments that leverage this advanced delivery system.

The MPN Technology® has shown promising results in preclinical studies, demonstrating the ability to bind with intracellular cancer targets and reduce tumor size. Libera Bio is actively pursuing partnerships to co-develop therapies that utilize this technology, which can encapsulate a variety of therapeutic payloads, including monoclonal antibodies and small molecules. The company is committed to bridging the gap from preclinical research to clinical development, ensuring that its transformative therapies can reach patients in need effectively and efficiently.

Spain

LiberaBio is a preclinical stage biotech that develops new oncology treatments based on the proprietary MPN technology. This nanotechnology actively targets tumor and metastatic cells and delivers small and large molecules to on-surface or intracellular targets. The company is creating new treatments by delivering novel antibodies targeting intracellular oncoproteins.

Libera Bio

Company Details